Erasca, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-11.
0001193125-26-216788
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-11.
0001193125-26-344611
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 10 previous paragraphs and 12 current paragraphs.
10 unchanged; 0 reworded; 2 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
There have been no material changes to the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 12, 2026, other than as set forth below.
Added paragraphs (2)
Current report
We are subject to securities class action litigation and a stockholder derivative complaint, and may become subject to additional litigation, which could result in substantial costs and divert management's attention.
Current report
On June 10, 2026, a purported securities class action complaint was filed against us and certain of our officers in the United States District Court for the Southern District of California. The complaint alleges violations of the federal securities laws and seeks damages, costs, and other unspecified relief. In August 2026, a purported stockholder derivative complaint was filed against us, our board of directors, and certain of our officers in the United States District Court for the Southern District of California. The complaint includes allegations of breaches of fiduciary duty and violations of federal securities laws and seeks damages, costs, and other unspecified relief. We believe the claims raised in both complaints are without merit and intend to defend each of the matters vigorously. However, litigation is inherently uncertain, and we cannot predict the outcome of either of these matters or any future litigation. Securities litigation and other legal proceedings can be expensive, time-consuming, and disruptive to normal business operations. Regardless of the outcome, such proceedings may result in substantial legal fees and other costs, divert management's attention from our business and operations, harm our reputation, affect our ability to attract and retain employees, and adversely impact our relationships with business partners, clinical investigators, patients, and investors. In addition, unfavorable outcomes could result in substantial monetary damages, judgments, settlements, fines, penalties, or other remedies that could have a material adverse effect on our business, financial condition, results of operations, and cash flows. We may also be subject to additional lawsuits, derivative actions, regulatory inquiries, or investigations relating to the same or similar subject matter. Any such proceedings could increase our costs and expose us to additional risks and uncertainties.